NGFR and melanoma: The prognostic potential of CD271 and p62 as biomarkers of disease progression was determined by their immunohistochemical expression in a cohort of FFPE primary naevi and melanomas of differing AJCC disease stage (Fig. 1a–c).28, 30 CD271 expression was significantly greater in stage III primary melanomas compared with naevi, stage I or stage II melanoma (all P < 0·001; Fig. 1b).